{"nctId":"NCT01578707","briefTitle":"A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia","startDateStruct":{"date":"2012-06","type":"ACTUAL"},"conditions":["Relapsed or Refractory Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"count":391,"armGroups":[{"label":"Ofatumumab (Arm A)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ofatumumab"]},{"label":"ibrutinib (Arm B)","type":"EXPERIMENTAL","interventionNames":["Drug: ibrutinib"]}],"interventions":[{"name":"ofatumumab","otherNames":[]},{"name":"ibrutinib","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* ECOG performance status of 0-1.\n* Diagnosis of CLL or SLL that meets IWCLL 2008 criteria.\n* Active disease meeting at least 1 of the IWCLL 2008 criteria for requiring treatment.\n* Must have received at least one prior therapy for CLL/SLL.\n* Considered not appropriate for treatment or retreatment with purine analog based therapy.\n* Measurable nodal disease by CT.\n* Patients must be able to receive outpatient treatment and laboratory monitoring at the institution that administers study drug for the entire study.\n\nExclusion Criteria:\n\n* Known CNS lymphoma or leukemia.\n* No documentation of cytogenetic and/or FISH in patient records prior to first dose of study drug.\n* Any history of Richter's transformation or prolymphocytic leukemia.\n* Uncontrolled Autoimmune Hemolytic Anemia (AIHA) or idiopathic thrombocytopenia purpura (ITP).\n* Prior exposure to ofatumumab or to ibrutinib.\n* Prior autologous transplant within 6 months prior to first dose of study drug.\n* Prior allogeneic stem cell transplant within 6 months or with any evidence of active graft versus host disease or requirement for immunosuppressants within 28 days prior to first dose of study drug.\n* History of prior malignancy, with the exception of certain skin cancers and malignancies treated with curative intent and with no evidence of active disease for more than 3 years.\n* Serologic status reflecting active hepatitis B or C infection.\n* Unable to swallow capsules or disease significantly affecting gastrointestinal function.\n* Uncontrolled active systemic fungal, bacterial, viral, or other infection.\n* History of stroke or intracranial hemorrhage within 6 months prior to the first dose of study drug.\n* Requires anticoagulation with warfarin.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013","description":"The primary objective of this study was to evaluate the efficacy of ibrutinib compared to ofatumumab based on independent review committee (IRC) assessment of progression-free survival (PFS) according to 2008 IWCLL guidelines.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR) by Independent Review Committee (IRC)","description":"Overall Response Rate per the IWCLL 2008 criteria as assessed by IRC, limited to the time of primary analysis 06 November 2013","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"42.6","spread":null}]}]}]},{"type":"SECONDARY","title":"OS (Overall Survival)","description":"OS analysis was conducted at the time of study closure, with no adjustment for crossover from the ofatumumab arm to the ibrutinib arm","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.1","spread":null},{"groupId":"OG001","value":"67.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Sustained Hemoglobin and Platelet Improvement","description":"Proportion of subjects with hemoglobin (HgB) increase \\>=20 g/L and platelet (PLT) increase \\>=50% over baseline continuously for \\>=56 days without blood transfusions or growth factors.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.6","spread":null},{"groupId":"OG001","value":"69.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":null},{"groupId":"OG001","value":"78.4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Progression Free Survival (PFS) by Investigator With up to 6 Years of Study Follow-up","description":"Long-Term Progression Free Survival as assessed by the investigator with up to 6 years of study follow-up","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"44.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Overall Response Rate (ORR) by Investigator","description":"Overall response per the IWCLL 2008 criteria as assessed by Investigator with up to 6 years of study follow-up","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4","spread":null},{"groupId":"OG001","value":"87.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":59,"n":191},"commonTop":["Diarrhoea","Fatigue","Cough","Nausea","Anaemia"]}}}